News|Articles|July 15, 2024

Biosimilars, a deflationary pull against the upward push of inflation

Author(s)Tony Hagen

Biosimilars generally enter the market priced at roughly 50% of the amount of their reference drugs.

With eight new biosimilars approved by midpoint 2024, these lower-cost biologics are one of the few deflationary factors in an otherwise relentlessly upward trend of medical cost inflation.

Related to this article

Pooja Roy, M.D., on Precedex-induced fever | CHEST 2026
Pooja Roy, M.D., of Houston Methodist Hospital, discusses how Precedex (dexmedetomidine), an ICU sedative, sometimes triggers noninfectious fever, sparking costly sepsis workups, and the need for a test could help clinicians identify the drug as a cause of fever in ICUs.
Eric K. Singhi, M.D., on lung cancer among younger adults
Young-onset lung cancer often strikes nonsmokers, and current screening based on smoking is not likely to find it, says Singhi, an assistant professor at UT MD Anderson Cancer Center in Houston. New risk-based screening, liquid biopsies, and breath tests aim earlier detection.